Clinical trials: Patients With Non-small Cell Lung Cancer
Pancreatic Cancer, Small Bowel Cancer
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF…
- Conditions
- Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma
- Trial name
- NCT04566393
- Testing
- Ulixertinib (BVD-523)
- Where
- 26 sites in United States
- Sponsor
- xCures
Carcinoma, Non-small-cell Lung
A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina
This is a study of the safety and effectiveness of atezolizumab in participants with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy.
- Trial name
- NCT03321695
- Where
- Argentina
- Volunteers
- 44 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer, Recurrent Non-Small Cell Lung Carcinoma
Yoga in Improving Quality of Life in Patients With Non-small Cell Lung Cancer Undergoing Treatment
The purpose of this research study is to evaluate the effects of yoga (including breathing exercises) on the quality of life in patients, diagnosed and undergoing standard treatments for non-small cell lung cancer.
- Trial name
- NCT02895503
- Testing
- Yoga, Support Group Therapy, FACT-L
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Virginia Commonwealth University
Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC)
Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer
The purpose of this study is to try to learn more about how small molecule kinase inhibitors work in treating lung cancer. Some early studies have shown that gefitinib, erlotinib and similar drugs are more likely to work if a…
- Trial name
- NCT00579683
- Testing
- Tumor core biopsy for RNA isolation
- Where
- 5 sites in United States
- Volunteers
- 228 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer, Small Cell Lung Cancer
Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer
This research trial studies genomic analysis in tissue and blood samples from young patients with lung cancer. Identifying specific gene mutations (changes in deoxyribonucleic acid [DNA]) may help doctors tailor treatment to…
- Trial name
- NCT02273336
- Testing
- cytology specimen collection procedure, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Southern California
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer
This clinical trial refines and tests the effect of a decision aid in improving decision-making in patients with non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Trial name
- NCT04946279
- Testing
- Best Practice, Informational Intervention, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Chemotherapeutic Agent Toxicity, Fatigue
First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chemotherapeutic Agent Toxicity, Fatigue, Lung Cancer, Musculoskeletal Complications
- Trial name
- NCT01097317
- Testing
- carboplatin, vinorelbine tartrate, neuromuscular electrical stimulation
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- Wales Cancer Trials Unit
Lung Cancer
Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC
The investigators prospectively evaluated in this study the efficacy and safety profiles of afatinib as 3rd or 4th line treatment after prior failure to systemic chemotherapy and first-generation EGFR-TKI under a Boehringer…
- Trial name
- NCT02625168
- Testing
- Afatinib, Erlotinib
- Where
- Hong Kong
- Volunteers
- 25 people
- Sponsor
- The University of Hong Kong
Lung Cancer
S9925: Collecting and Storing Samples From Patients With Lung Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and sputum from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00920010
- Testing
- biologic sample preservation procedure
- Where
- 431 sites in United States
- Volunteers
- 2,264 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00653250
- Testing
- celecoxib, biopsy, therapeutic conventional surgery
- Volunteers
- 22 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lung Cancer
Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for non-small cell lung cancer.
- Trial name
- NCT00004100
- Testing
- cisplatin, gemcitabine hydrochloride, vinorelbine tartrate
- Where
- 29 sites in Italy
- Sponsor
- Istituto Nazionale per lo Studio e la Cura dei Tumori
Breast Cancer, Non Small Cell Lung Cancer
Metronomic Oral Vinorelbine in Patients With Metastatic Tumors
Patients with recurrent or metastatic solid tumors receive oral vinorelbine at one of three different doses (30 or 40 or 50 mg).
- Conditions
- Breast Cancer, Non Small Cell Lung Cancer, Prostate Cancer
- Trial name
- NCT00278070
- Testing
- vinorelbine oral formulation
- Where
- 11 sites in Greece
- Sponsor
- Hellenic Cooperative Oncology Group
Non-Small Cell Lung Cancer
KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)
The objectives of this study are to assess the safety and efficacy of single agent Tagrisso (Osimertinib, hereinafter "the study drug") in a real world setting in adult patients with advanced or metastatic, epidermal growth…
- Trial name
- KOREA (NCT02777567)
- Where
- South Korea
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Lung Cancer
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003284
- Testing
- filgrastim, carboplatin, etoposide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Non-Small Cell Lung Cancer (NSCLC)
Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1
Importance: EGFR tyrosine kinase inhibitors (EGFR-TKIs) and PD-1/PD-L1 immune checkpoint inhibitors are widely used in the treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT07036016
- Testing
- EGFR-TKI, PD-1/PD-L1 inhibitor, EGFR-TKI combined with PD-1/PD-L1
- Volunteers
- 67,818 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Carcinoma, Non-Small-Cell Lung
A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery
This is a multicenter, observational cohort study in China with both primary prospective data collection and retrospective collection of prior treatment information from medical records, which enrolls and follows patients who are…
- Trial name
- NCT05872763
- Where
- 12 sites in China
- Volunteers
- 901 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer
Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer
With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epidermal growth factor receptor…
- Trial name
- NCT01522833
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- SCRI Development Innovations, LLC
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Trial name
- NCT00068497
- Testing
- gefitinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer, Leptomeningeal Metastasis
A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis
Leptomeningeal metastasis (LM) is one of the disastrous events when managing advanced Non-small cell lung cancer (NSCLC) due to a grave prognosis.
- Trial name
- NCT02803619
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Neoplasms
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who…
- Trial name
- NCT03194893
- Testing
- Alectinib, Crizotinib
- Where
- 29 sites in United States, France and 7 more
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche